Benitec Biopharma Inc.

BNTC

Explore Our Financial Data > Companies > Benitec Biopharma Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	BNTC
CIK	0001808898
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	3940 TRUST WAY, HAYWARD, CA, 94545
Website	benitec.com
Phone	(510) 780-0819
CEO	Jerel A. Banks
Employees	20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-20.86 million
Net Income	$-20.86 million
Net Income to Common	$-20.86 million
EPS	$-1.96

View All

Balance Sheet

Cash	$103.58 million
Assets	$105.21 million
Liabilities	$7.64 million
Common Equity	$97.57 million
Liabilities & Equity	$105.21 million

View All

Cash Flow Statement

Net Income	$-20.86 million
Cash From Operating Activities	$-18.67 million
Cash From Investing Activities	$-18,000.00
Cash From Financing Activities	$108.01 million
Change in Cash	$89.49 million

View All

Calculations

NOPAT	$-15.68 million
EBITDA	$-22.02 million
Price to Earnings	N/A
Price to Book	$4.96
ROE	-48.23%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Benitec Biopharma Provides Operational Updates

-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects Enrolled into Cohort 1, and the Data Safety Monitoring Board Recommended Continuation of Subject Enrollment for the Phase 1b/2a Clinical Treatment Study- -Following the Positive Data Safety Monitoring Board Recommendation, Enrollment of Cohort 2 is E

Article Link

Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?

Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Article Link

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Article Link

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Article Link

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Article Link